The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Fri., Mar. 29, 9:19 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #81. Thermo Fisher Scientific Inc. One Lambda, Inc.

Acquirer: Thermo Fisher Scientific Inc. (NYSE:TMO)
Acquiree: One Lambda, Inc.
Details: Thermo Fisher Scientific Inc.has completed its previously announced acquisition of One Lambda, Inc., the leader in transplant diagnostics. Based in Canoga Park, Calif., One Lambda has approximately 320 employees and had 2011 revenue of $182 million. The business will become part of Thermo Fisher's Specialty Diagnostics Segment.

Thermo Fisher Scientific is engaged in serving science. Co.'s segments include: Life Sciences Solutions, which provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of disease; Analytical Instruments, which provides instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field; and Specialty Diagnostics, which provides diagnostic test kits, reagents, culture media, instruments and associated products; and Laboratory Products and Biopharma Services, which provides virtually things needed for the laboratory.

Thermo Fisher Scientific SEC Filing Email Alerts Service


Open the TMO Page at The Online Investor »

Company Name: 
Thermo Fisher Scientific Inc
Stock buyback: 
TMO buyback
Website: 
www.thermofisher.com
Sector: 
Biotechnology
Number of ETFs Holding TMO: 
109
Total Market Value Held by ETFs: 
$25.97B
Total Market Capitalization: 
$216.90B
% of Market Cap. Held by ETFs: 
11.97%
 

Open the TMO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree TMO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.31 out of 4)
45th percentile
(ranked lower than approx. 55% of all stocks covered)

Analysts' Target Price:
TMO Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 81 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.